Medicines Formulary

Medicines A–Z

A

Drug name	NICE TAs	Comments
Atropine suplhate 1% single use drops		Specialist ophthalmologist recommendation
Atropine tablets		For Myaesthenia Gravis only
Avacopan (Tavneos®)	TA825: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
Avalglucosidase	TA821: Avalglucosidase alfa for treating Pompe disease
Avatrombopag	TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avatrombopag (Doptelet®)	TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Aveeno cream		Amber - oncology use Green - paediatrics only
Avelumab (Bavencio®)	TA517 - Avelumab for treating metastatic Merkel cell carcinoma TA644 - Avelumab with axitinib for untreated advanced renal cell carcinoma
Aviptadil 25mcg / Phentolamine 2mg intracavernosal injection (Invicorp®)		Approved on formulary December 2017. Specialist initiation. Third line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil. To be reviewed within 12 months to assess alprostadil supply issues and patent expiry
Axicabtagene ciloleucel (Yescarta®)	TA872 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.